Carregant...

Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors

OBJECTIVES: Inhibition of either vascular endothelial growth factor receptor (VEGFR) or mammalian target of rapamycin (mTOR) signaling improves outcomes in patients with several advanced solid tumors. We conducted a phase I trial of temsirolimus with pazopanib to investigate the feasibility of simul...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Semrad, Thomas J., Eddings, Courtney, Dutia, Mrinal P., Christensen, Scott, Lara, Primo N.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4153755/
https://ncbi.nlm.nih.gov/pubmed/23698253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0b013e3283618b7b
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!